Payment overview · 2025
General Payments
$1,669.05
89 reported records · 21 companies
Healthcare provider profile · identity verified
William Jonathan Dailey, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MONTGOMERY, AL · NPI 1144314642
Verified facts
What the public records show
CMS Open Payments records show William Jonathan Dailey, MD received $1,669.05 in general payments during 2025 across 89 reported records.
ABBVIE INC. accounted for 12.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Paxlovid, Rybelsus, Synthroid, Trelegy Ellipta, Veozah.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Viberzi by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Myrbetriq by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veozah as an associated drug or biological on 82795 records involving 35863 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Veozah by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 236 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $209.37 | 12.5% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $187.47 | 11.2% | 10 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $153.35 | 9.2% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $147.95 | 8.9% | 9 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $114.32 | 6.8% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $111.14 | 6.7% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $109.52 | 6.6% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $108.68 | 6.5% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $96.74 | 5.8% | 5 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $87.00 | 5.2% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $74.20 | 4.5% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $68.91 | 4.1% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.64 | 2.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.25 | 1.9% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $24.75 | 1.5% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $21.27 | 1.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.81 | 1.2% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $20.35 | 1.2% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $17.44 | 1.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.14 | 1.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.75 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,669.05 | 89 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $167.64 | 11 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $115.18 | 7 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $114.32 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $112.06 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $112.06 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $111.14 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $111.14 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $96.74 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $90.51 | 4 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $87.00 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $86.88 | 4 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $84.27 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $74.20 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $69.08 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $68.91 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $57.44 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $57.44 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $52.08 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $46.52 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $44.84 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $41.73 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $39.09 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $39.09 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $39.09 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $38.54 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $32.64 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.25 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $24.69 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.80 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $21.27 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 236 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 51 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 52 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 64 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 116 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 84 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 31 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 78 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 119 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Veozah veozah |
2025 | Veozah | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
119 | 29 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
78 | 17 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Veozah open payments reported associated product |
CMS Open Payments — General Payments 82795 supporting records · 35863 recipient NPIs · example record 1238560678 |
Veozah · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
64 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
64 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
116 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
84 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
78 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
236 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
31 | 31 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
52 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 788 | 203 |
| Alprazolam | Alprazolam | 699 | 122 |
| Amlodipine Besylate | Amlodipine Besylate | 617 | 173 |
| Atorvastatin Calcium | Atorvastatin Calcium | 520 | 146 |
| Pantoprazole Sodium | Pantoprazole Sodium | 494 | 139 |
| Losartan Potassium | Losartan Potassium | 400 | 119 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 397 | 86 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 369 | 112 |
| Potassium Chloride | Potassium Chloride | 366 | 97 |
| Temazepam | Temazepam | 363 | 52 |
| Zolpidem Tartrate | Zolpidem Tartrate | 356 | 58 |
| Gabapentin | Gabapentin | 317 | 85 |
| Simvastatin | Simvastatin | 308 | 82 |
| Pravastatin Sodium | Pravastatin Sodium | 307 | 92 |
| Meloxicam | Meloxicam | 292 | 83 |
| Hydrochlorothiazide | Hydrochlorothiazide | 285 | 75 |
| Montelukast Sodium | Montelukast Sodium | 284 | 90 |
| Tramadol Hcl | Tramadol Hcl | 280 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 269 | 81 |
| Clonazepam | Clonazepam | 251 | 43 |
| Omeprazole | Omeprazole | 243 | 61 |
| Eliquis | Apixaban | 236 | 42 |
| Carvedilol | Carvedilol | 233 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 233 | 67 |
| Lorazepam | Lorazepam | 222 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 202 | 54 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 184 | 26 |
| Donepezil Hcl | Donepezil Hcl | 172 | 35 |
| Trazodone Hcl | Trazodone Hcl | 172 | 52 |
| Lisinopril | Lisinopril | 156 | 47 |
| Bupropion Xl | Bupropion Hcl | 136 | 42 |
| Tizanidine Hcl | Tizanidine Hcl | 136 | 42 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 135 | 35 |
| Allopurinol | Allopurinol | 132 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 131 | 36 |
| Sertraline Hcl | Sertraline Hcl | 130 | 30 |
| Famotidine | Famotidine | 127 | 47 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 127 | 27 |
| Furosemide | Furosemide | 124 | 39 |
| Metformin Hcl | Metformin Hcl | 124 | 41 |
| Prednisone | Prednisone | 124 | 82 |
| Synthroid | Levothyroxine Sodium | 119 | 29 |
| Celecoxib | Celecoxib | 118 | 32 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 118 | 34 |
| Bumetanide | Bumetanide | 116 | 31 |
| Ezetimibe | Ezetimibe | 116 | 32 |
| Mounjaro | Tirzepatide | 116 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 31 |
| Estradiol | Estradiol | 96 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 96 | 27 |
| Ondansetron Odt | Ondansetron | 96 | 40 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 95 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 95 | 29 |
| Atenolol | Atenolol | 94 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 91 | 68 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 91 | 16 |
| Glimepiride | Glimepiride | 90 | 32 |
| Azithromycin | Azithromycin | 88 | 72 |
| Silodosin | Silodosin | 87 | 19 |
| Ozempic | Semaglutide | 84 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 29 |
| Myrbetriq | Mirabegron | 78 | 17 |
| Rybelsus | Semaglutide | 78 | 16 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 76 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 75 | 18 |
| Januvia | Sitagliptin Phosphate | 73 | 17 |
| Cefuroxime | Cefuroxime Axetil | 71 | 60 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 71 | 55 |
| Valacyclovir | Valacyclovir Hcl | 71 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 70 | 56 |
| Dicyclomine Hcl | Dicyclomine Hcl | 68 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 68 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 67 | 21 |
| Ramipril | Ramipril | 66 | 17 |
| Diazepam | Diazepam | 65 | 16 |
| Metformin Hcl Er | Metformin Hcl | 65 | 18 |
| Telmisartan | Telmisartan | 65 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 18 |
| Hydrocortisone | Hydrocortisone | 64 | 22 |
| Jardiance | Empagliflozin | 64 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 63 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 61 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 18 |
| Pregabalin | Pregabalin | 61 | suppressed |
| Finasteride | Finasteride | 60 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 16 |
| Meclizine Hcl | Meclizine Hcl | 56 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 14 |
| Spironolactone | Spironolactone | 55 | 17 |
| Glipizide | Glipizide | 54 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 53 | 12 |
| Gemtesa | Vibegron | 52 | 15 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 51 | 21 |
| Farxiga | Dapagliflozin Propanediol | 51 | 11 |
| Fluconazole | Fluconazole | 51 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 50 | 16 |
| Torsemide | Torsemide | 50 | 19 |
| Buspirone Hcl | Buspirone Hcl | 49 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 48 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 47 | 12 |
| Fenofibrate | Fenofibrate | 47 | 12 |
| Linzess | Linaclotide | 46 | 13 |
| Indapamide | Indapamide | 45 | 16 |
| Testosterone | Testosterone | 44 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 43 | 11 |
| Sucralfate | Sucralfate | 42 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 41 | 13 |
| Levofloxacin | Levofloxacin | 41 | 31 |
| Methylphenidate Hcl | Methylphenidate Hcl | 41 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 41 | 13 |
| Ramelteon | Ramelteon | 41 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 41 | 11 |
| Dutasteride | Dutasteride | 40 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 38 | 13 |
| Lansoprazole | Lansoprazole | 38 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Chlorthalidone | Chlorthalidone | 36 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 36 | suppressed |
| Premarin | Estrogens, Conjugated | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | 12 |
| Loperamide | Loperamide Hcl | 34 | 16 |
| Viberzi | Eluxadoline | 34 | suppressed |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 31 | 31 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 31 | suppressed |
| Belsomra | Suvorexant | 30 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Cephalexin | Cephalexin | 29 | 18 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Methocarbamol | Methocarbamol | 29 | 15 |
| Flecainide Acetate | Flecainide Acetate | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | 16 |
| Colestipol Hcl | Colestipol Hcl | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Klor-Con 10 | Potassium Chloride | 25 | suppressed |
| Metolazone | Metolazone | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Xtampza Er | Oxycodone Myristate | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 20 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Colchicine | Colchicine | 23 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 21 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 21 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 15 |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 18 |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Fluocinonide | Fluocinonide | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Zaleplon | Zaleplon | 18 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | suppressed |
| Armour Thyroid | Thyroid,pork | 14 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 14 | suppressed |
| Procto-Med Hc | Hydrocortisone | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Desoximetasone | Desoximetasone | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Mesalamine Er | Mesalamine | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Budesonide Dr | Budesonide | 11 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Oxazepam | Oxazepam | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Tobramycin | Tobramycin | 11 | 11 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
| Veozah | Fezolinetant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,669.05 · 89 records | ABBVIE INC. | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, Auvelity, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, INGREZZA, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, SPRAVATO, SYNTHROID, Symbravo, TRELEGY ELLIPTA, Tymlos, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, ZEPBOUND | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error